English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51826359    線上人數 :  309
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"zhong zhe lin"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 51-75 / 125 (共5頁)
<< < 1 2 3 4 5 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-06-10T06:10:57Z Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-06-10T06:10:57Z Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma ZHONG-ZHE LIN; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:56Z Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2022-06-10T06:10:56Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏 2022-06-10T06:10:55Z Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏 2022-06-10T06:10:55Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2022-06-10T06:10:54Z Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏 2022-06-10T06:10:54Z The Short- and Long-term Causal Relationships Between Self-compassion, Trait Mindfulness, Caregiver Stress, and Depressive Symptoms in Family Caregivers of Patients with Lung Cancer Hsieh C.-C.; ZHONG-ZHE LIN; Ho C.-C.; Yu C.-J.; Chen H.-J.; Chen Y.-W.; Hsiao F.-H.
臺大學術典藏 2022-06-10T06:10:54Z Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life Hsieh C.-C.; Ho C.-C.; ZHONG-ZHE LIN; Yu C.-J.; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H.
臺大學術典藏 2022-06-10T06:10:53Z Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials Chen B.-B.; ZHONG-ZHE LIN; Shao Y.-Y.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏 2022-06-10T06:10:53Z Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏 2022-06-10T06:10:52Z Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma Chen C.-T.; Liu T.-H.; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; ZHONG-ZHE LIN
臺大學術典藏 2022-06-10T06:10:52Z Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; ZHONG-ZHE LIN; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:51Z Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN; Youkstetter J.; Hazra S.; Sen S.; Cheng A.-L.; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K.
臺大學術典藏 2022-06-10T06:10:51Z The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients Hsiao F.-H.; ZHONG-ZHE LIN; Huang F.-Y.; Lai Y.-M.; Chen Y.-T.; Shih J.-Y.; Ho C.-C.; Yu C.-J.; Hsieh C.-C.
臺大學術典藏 2022-06-10T06:10:50Z Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma Shao Y.-Y.; Kuo H.-Y.; Jeng Y.-M.; Wu Y.-M.; Wang H.-P.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏 2021-08-11T03:46:54Z Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.
臺大學術典藏 2021-08-11T03:46:53Z Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma Lu Y.-S.; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN; Chen T.-J.; Cheng A.-L.; Chen C.-S.
臺大學術典藏 2021-08-11T03:46:53Z Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; ZHONG-ZHE LIN; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.
臺大學術典藏 2021-08-11T03:46:53Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏 2021-08-11T03:46:52Z The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏 2021-08-11T03:46:52Z Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L.
臺大學術典藏 2021-08-11T03:46:52Z Sunitinib-induced myxedema coma Chen S.-Y.; Kao P.-C.; ZHONG-ZHE LIN; Chiang W.-C.; Fang C.-C.
臺大學術典藏 2021-08-11T03:46:52Z High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y.
臺大學術典藏 2021-08-11T03:46:51Z Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L.

顯示項目 51-75 / 125 (共5頁)
<< < 1 2 3 4 5 > >>
每頁顯示[10|25|50]項目